Up­start maps plans to build fi­bro­sis pipeline; FDA ex­tends re­view pe­ri­od for Lil­ly’s baric­i­tinib

• A group of aca­d­e­m­ic in­ves­ti­ga­tors in Toron­to, work­ing through MaRS In­no­va­tion, are spin­ning out new tech to launch a biotech start­up dubbed Fi­bro­cor in part­ner­ship with Ger­many’s Evotec. Launched with about $2.1 mil­lion in seed mon­ey, they’ll work on iden­ti­fy­ing a lead pro­gram for fi­bro­sis in 2018.

• The FDA will take some added time to re­view Eli Lil­ly’s ap­pli­ca­tion for baric­i­tinib. The phar­ma gi­ant has filed some added da­ta analy­sis on the rheuma­toid arthri­tis drug that reg­u­la­tors will need time to re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER